News / Taiwan / cnyes
AJ Biologics Files for Phase 3 Clinical Trial of SBMA Drug with US FDA
Health Technology · Biotechnology · cnyes · 2026-09-04
7754
AJ Biologics has submitted a Phase 3 clinical trial application to the FDA for its SBMA treatment, AJ201, aiming for a Q4 launch to bolster its global licensing potential.
What Happened
Clinical Progress: AJ Biologics (7754-TW) has officially submitted a Phase 3 pivotal trial application to the U.S. FDA for its core drug candidate, AJ201, designed to treat Spinal and Bulbar Muscular Atrophy (SBMA). Pending a standard 30-day FDA review period without requests for further information, the global clinical trial is expected to commence as early as the fourth quarter of this year.
Trial Strategy: The Phase 3 study aims to enroll 200 patients globally, with the timeline subject to adjustments based on international licensing partners' development strategies. AJ201 has already secured Orphan Drug Designation from both the FDA and EMA, along with Fast Track designation, with patent protection potentially extending until 2044.
Strategic Value: The company highlights that AJ201 is currently the only known drug candidate for SBMA to reach the Phase 3 clinical stage globally. This milestone significantly enhances the drug's market value and strengthens the company's negotiating position for future global licensing and partnership agreements.
Market Potential: Market research from L.E.K. Consulting indicates that there are over 12,000 SBMA patients worldwide. The potential annual market for this treatment is estimated to reach as high as $2.5 billion, underscoring the substantial commercial opportunity for this rare disease therapy.
Read original
More in Health Technology
Health Technology · cnyes · 2026-09-04
Han-Kang-KY's subsidiary, FBD Biologics, has submitted an IND application to the FDA for HCB303, a tri-specific immunotherapy targeting advanced solid tumors.
7827
Health Technology · yonhap_finance · 2026-09-04
Curacle has decided to raise approximately 100 billion KRW through a rights offering to secure working capital, issuing 7.1 million new shares.
115180
Health Technology · yonhap_finance · 2026-09-04
The Korea Exchange's tech-specialized listing program has reached 300 companies 21 years after its inception, solidifying its role in KOSDAQ growth.
196170, 386380, 950200, 950220, 950250
Latest in Taiwan
Health Technology · cnyes · 2026-09-04
Han-Kang-KY's subsidiary, FBD Biologics, has submitted an IND application to the FDA for HCB303, a tri-specific immunotherapy targeting advanced solid tumors.
7827
Electronic Technology · economic_daily · 2026-09-04
Taiwan stocks surged 693 points today as TSMC led a broad market rally, capping off a second straight week of gains while investors monitor upcoming Fed and global central bank policy decisions.
2303, 2308, 2317, 2327, 2330, 2344, 2368, 2408, 2454, 2464, 3017, 3037, 3081, 3189, 3231, 3363, 3443, 3711, 6147, 6442, 8046
Electronic Technology · economic_daily · 2026-09-04
AI server stocks rallied today, led by a 7% surge in Compal, as strong demand for computing power and increased capital expenditure from CSPs drive growth for Taiwanese suppliers.
2317, 2324, 2330, 2356, 2382, 2454, 3231, 3661, 6669
Electronic Technology · cnyes · 2026-09-04
As AI development remains in its early stages, Taiwan's robust hardware manufacturing ecosystem continues to secure its position as a critical global hub.